In oncology clinical trials, many patients spend their final months at a central clinical trial facility far from home for “mandatory” protocol visits/diagnostic testing. Studies suggest that the travel strain may be greatest among patients living in low‐income areas and/or participating in early-phase studies. In this regard, rare cancers constitute a special unmet need with limited therapeutic options and few trials.